Q3 2020 Sales Performance

Trelegy: growing the market with leading performance gsk Strong performance with room to grow £194m in Q3, +45% ■ Substantial COPD growth opportunity ■ Launched in 43 markets including China and Japan Market leading in US and other major markets US triple therapy market share ■ <25% maintenance patients on triple therapy today 50% 40% 30% 20% 10% 0% Further growth & differentiation opportunity in asthma 5.8m US adult asthma patients on ICS/LABA-30% uncontrolled O US approval received September 2020 O Only once-daily triple approved for asthma in US; filed in EU and Japan 1 Lancet 2016 2. Source: IQVIA APLD; w/e Sep 18th, 2020 Jan-19 Mar-19 May-19 Trelegy Symbicort Trelegy Share of Triple Therapy Patients² Jul-19 Sep-19 Nov-19 Jan-20 Mar-20 May-20 Jul-20 Sep-20 Symbicort Gx + Spiriva Advair + Advair Gx + Spiriva 3. Treated with Maintenance: IQVIA Claims Data; Jan - Dec 2019; Patients on Triple Therapy and % Patients on Trelegy: Sourced from IQVIA Claims Data; Aug 2020 Unmet need remains 6.4m COPD patients on maintenance in the US 1.7m treated with triple therapy 714k treated with Trelegy Substantial room to grow the class with <27% of maintenance on a triple and only 42% of those on a triple taking Trelegy³ 23

View entire presentation